The 13th Aging Research & Drug Discovery meeting ran from 1 to 3 October 2026 at Harvard. It is normally an insider event: mouse lifespan curves, mitochondrial pathways, the usual arguments about which hallmark matters most. This year it had a government panel on it, and four senior people from the US Food and Drug Administration showed up to sit on it.[1]
What they said got compressed into a headline that is not quite right: FDA recognises aging as a disease. It did not. But something did happen, and the gap between what happened and what was reported is worth understanding, because it tells you roughly how long the wait is going to be.
What was actually announced
Steven Kozlowski, the FDA’s chief scientist, said that aging and longevity will be one of the topics in the agency’s next Focus Areas of Regulatory Science report.[2] The FARS report is an internal priority-setting document: it lists the areas where the FDA thinks its own scientific capacity needs targeted investment, so that when products in that area arrive, the agency knows how to evaluate them. The last edition came out in 2022.[3] The update including aging is targeted for fiscal year 2027.
Lowell Zeta, deputy commissioner for strategic initiatives, framed it in bigger terms — “a defining moment, an inflection point for the future of FDA” — and the room applauded.[2] It is worth being precise about what earns applause here. A FARS listing does not classify aging as a disease. It does not create an indication. It does not approve anything. What it does is commit the agency to building the measurement tools it would need if it ever wanted to.
That is genuinely new. For most of the last decade the geroscience field’s complaint was not that the FDA had said no — it was that there was nobody to ask. Justin Penzenstadler, acting associate director in the office that covers cardiology, haematology, endocrinology and nephrology, identified his office as the one responsible for aging as a regulatory indication and told sponsors to stop asking hypothetical questions and start submitting actual protocols through the investigational new drug process.[2] A named office and a named route in is, bureaucratically speaking, the whole difference between a field and a hobby.
Why there is still no box marked “aging”
A drug is not approved to be good for you. It is approved for an indication: a defined condition, in a defined population, measured by a defined endpoint. Aging fails that test in an awkward way — not because it is not real, but because everybody has it, and there is no agreed instrument that says how much of it you have.
This is the wall the repurposed-drug pipeline has been standing in front of for years. The TAME proposal — Targeting Aging with Metformin, outlined by Nir Barzilai and colleagues in 2016 — was explicitly designed as a workaround.[4] Rather than claim metformin (C4H11N5) treats aging, it proposed a composite endpoint: time to the first occurrence of any of several major age-related diseases. The logic was that if one cheap drug delays cardiovascular disease, cancer, dementia and death as a bundle, it is doing something upstream of all of them. Ten years on, TAME is still better known as a design than as a completed trial.
Route one: one disease at a time
The first pathway officials described is the unglamorous one. A drug targeting an aging mechanism shows benefit in one recognised age-related condition. Then another. Then another. At some point the pattern itself becomes the evidence that the effect is broader than any single disease.[1]
This is slow and expensive and it is also how rapamycin (C51H79NO13) and its analogues would most plausibly arrive, one indication at a time. The advantage is that it requires no new regulatory invention at all. Every step uses machinery that already exists. The disadvantage is that it could take a generation, and that nobody gets to put “anti-aging” on the label at the end of it.
Route two: measure the decline itself
The second pathway is more interesting and much less built. Instead of chasing diseases, you define age-related deterioration directly — across cognition, frailty, sensory function, physical capacity — and treat improvement or preservation of that as the outcome.[1] Kozlowski floated the idea of a “G factor” for aging: a single quantifiable component shared across chronic diseases, analogous to the general-intelligence factor in psychometrics.
The obstacle is not conceptual. It is that choosing which instruments count, and proving they mean something, is years of consensus work. A 2025 expert effort on exactly this question — which endpoints geroscience trials should use — was still framed as a path towards consensus rather than a conclusion.[5] Penzenstadler’s own expectation was sobering: the earliest approvable trials, he said, will look at prevention of age-related comorbidities or mortality, with functional measures collected alongside rather than relied upon.[2]
In other words: hard endpoints first. Deaths and heart attacks. The softer, faster measures come later, once there is data showing they predict the hard ones.
The thirty-year problem
The most quotable line of the panel was also the most deflating. “We’re thinking about potentially treating somebody for thirty years to derive a couple-year benefit,” Penzenstadler said.[2]
Sit with that for a moment, because it reframes the entire field. A cancer drug can show a survival signal in two years. A prevention drug aimed at healthy people has to be given to people who are fine, for decades, before the curves separate. The safety bar is correspondingly brutal: a side effect that would be tolerable in a terminal patient is unacceptable in a 45-year-old who feels well. And no commercial sponsor can run a thirty-year trial.
This is precisely why biomarkers matter so much to this field, and why the FDA building biomarker capacity is the real news. Shorten the trial, and the economics change. Fail to shorten it, and nothing gets built regardless of how good the biology is. The ceiling on human lifespan has not moved much in decades, and trial length is a large part of why.
The live test case: GLP-1 drugs and the aging clocks
At the same meeting, Eli Lilly and Novo Nordisk presented data arguing that their obesity drugs slow biological aging as read by molecular clocks.[6] Novo used proteomic clocks in a study of 10,052 participants, half on drug and half on placebo; Lilly used epigenetic clocks in a smaller sample. The reported effect was roughly two to three years of slowed aging, and as much as four years on a clock built from heart proteins.
Steve Horvath, who built some of the original clocks, called two years “a pretty strong effect, in my book.” He and Vadim Gladyshev both added the same caveat: this was shown in people with obesity, and it does not follow that a healthy-weight person would get the same thing.[6] Muscle loss on these drugs is a live concern in its own right.
Two things about this deserve flagging. First, these were conference presentations by the companies that sell the drugs, not peer-reviewed publications — the normal rules about provisional data apply. Second, there is already a hard-endpoint result sitting underneath them. SELECT randomised 17,604 adults with cardiovascular disease and overweight or obesity but no diabetes to semaglutide 2.4 mg or placebo, and found major cardiovascular events in 6.5% versus 8.0% over a mean 39.8 months — a hazard ratio of 0.80.[7] That is the kind of evidence Penzenstadler was describing. Whether that makes these drugs anti-aging drugs is a different and much shakier claim than whether they prevent heart attacks.
Why a biological-age number is not yet enough
The panel drew a distinction that most consumer coverage of epigenetic age tests skips entirely, and it is the distinction that decides how fast any of this moves.
A prognostic biomarker tells you something about risk. People with accelerated epigenetic age tend to do worse. That is a real and reproducible observation, and it is also compatible with the clock being a passive readout — a thermometer, not a thermostat.
A surrogate endpoint is a much stronger claim. It requires evidence that when a treatment moves the marker, the clinical outcome moves with it. Not that the marker correlates with risk, but that changing it changes what happens to the patient. Almost no aging clock has been shown to clear that bar.
Which means a company can truthfully say its drug lowered customers’ biological age by three years and still have demonstrated nothing an approval could be built on. This is the quiet fault line running under the entire age-reversal market — including the contest launched this autumn in which roughly 500 competitors will spend six months racing to reverse their measured biological age.[8] It is a competition to move a number whose meaning, when deliberately targeted, is exactly what regulators have not yet accepted.
What this does and does not change
If you are taking something today in the hope of slowing your own aging, nothing about your situation changed in Boston. No drug became available, nothing was approved, and no supplement acquired evidence it did not have on 30 September.
What changed is institutional, and institutional changes are slow and real at the same time. There is now a named office, an invitation to file protocols, and a commitment to put aging in a document that shapes where the agency builds expertise. The honest timeline, read off the officials’ own words, is years to a usable biomarker framework and longer to anything approved. The field’s own asks — a shared biomarker registry, recurring meetings between regulators and industry — are the asks of people who expect to be at this for a decade.[1]
That is still the most concrete thing to happen to longevity medicine’s regulatory prospects in years. It just happens to look like paperwork rather than a breakthrough, which is why it was always going to be reported badly.
Common questions
Has the FDA recognised aging as a disease?
No. Officials said aging and longevity will be included as a topic in the next Focus Areas of Regulatory Science report, targeted for fiscal year 2027. That document sets research priorities for the agency. It is not a disease classification, and it does not create an indication a drug can be approved for.
Could a drug ever be approved to treat aging?
Two routes were described. One accumulates evidence disease by disease until the breadth of effect speaks for itself. The other defines measurable decline across domains such as cognition, frailty and physical capacity and uses that as the outcome. Both need outcome measures regulators accept, and the FDA’s own expectation is that the earliest approvable trials will still use hard endpoints — comorbidities and mortality.
Can a biological age test count as evidence in a drug trial?
Not as proof of benefit, not yet. Predicting risk and serving as a surrogate endpoint are different standards, and aging clocks have largely only cleared the first. If you want to know where your own numbers sit in the meantime, the useful ones are still ordinary blood markers rather than a proprietary age score.